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Fetal tissues are frequently discarded before (amniocentesis) or after birth, which both facilitates stem
cell access and helps to overcome ethical concerns. In the present study, we aimed to isolate and
characterize stem cells from the allantoic and amniotic ﬂuids (ALF; AMF) of third trimester canine
fetuses. This gestation age has not been previously explored for stem cells isolation. The gestational age,
cell culture conditions and method of isolation used in this study allowed for the establishment and
efﬁcient expansion of ALF and AMF cells. We showed that the majority of ALF and ALF cells express the
stem cell markers, such as vimentin, nestin and cytokeratin 18 (CK18). Under appropriate culture
conditions AMF derived cells can undergo differentiation into osteogenic, adipogenic, chondrogenic and
neuron-like lineages. ALF derived cells showed adipogenic, and chondrogenic potential. Therefore, ALF
and AMF cells derived at the third gestation trimester can be qualiﬁed as progenitor stem cells,
accordingly referred as (alantoic ﬂuid progenitor/stem) ALF PS cells and (amniotic ﬂuid progenitor/stem)
AMF PS cells.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Recent studies have highlighted the therapeutic value of stem
cells derived from both extra-embryonic and fetal tissues [1e3].
There is little ethical controversy in harvesting extra-embryonic
tissues, which are routinely discarded at parturition. Extraembry-
onic tissues are expected to provide a large number of progenitor/
stem (PS) cells at different stages ofmaturation, due to the expanded
volume. These PS cells have a low chance of rejection in allogeneic
transplantation and are well-tolerated in xenotransplants [4,5]. It
has been shown that extra-embryonic, tissue-derived stem cells
actively proliferate following transplantation in vivo and produce
high levels of angiogenic and trophic factors, such as vascular and
endothelial growth factor (VEGF),ﬁbroblast growth factor (FGF), and
transforming growth factor-b (TGF-b) and others [6]. Much researchInstituto Butantan, Av. Vital
37267222; fax: þ55 11 3885
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evier OA license.has therefore been conducted on the isolation of these cells. In
mammals, amniotic ﬂuid (AMF) consists of different cell types such
as epithelioid, amniotic ﬂuid-speciﬁc and ﬁbroblastic cells [7].
Therefore, stemcellswith distinct properties aswell asmulticellular
stemcell population,which composedbydifferent cells types canbe
isolated fromAMF [8]. Thus, Prusa and co-workers (2003) isolated at
the ﬁrst trimester of gestation human AMF multicellular stem cell
population, which was composed by the cells at various stages of
maturity, from genuine stem cells to committed progenitors found
in different proportions [9e11]. These multicellular stem cells
population consists of immature Oct-4 POU family transcription
factor (a marker of pluripotent stem cells) expressing stem cells and
typical mesenchymal stem cells (MSC) [7]. Other authors reported
isolation of MSCs from human AMF at the second trimester of
gestation during amniocentesis. These cells are similar toMSCs from
other sources express such markers, as CD90, CD105, CD73, CD166
and differentiate into neurons, hepatocytes, ﬁbroblasts, adipocytes,
osteocytes, myocytes and chondrocytes [3,5,9e13]. Isolation of
canine AMF MSCs has been reported, while the authors did not
specify the caninegestational age. These cellswere abledifferentiate
into neuronal, adipose, bone and cartilage [14,15]. These cells are
similar to MSCs from other sources express such markers, as CD90,
CD105, CD73, CD166 and differentiate into neurons, hepatocytes,
ﬁbroblasts, adipocytes, osteocytes, myocytes and chondrocytes
[3,5,9e13]. Isolation of canine AMF MSCs has been reported, while
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were able differentiate into neuronal, adipose, bone and cartilage
[15].
Allantoic ﬂuid (ALF) has been explored only marginally as
a source of PS cells. In mice, the fetal component, which derives
from the fused allantois and chorion, has been found to be a source
of hematopoietic stem cells [16]. However studies in other animals
are lacking.
The dogs are good model for stem cell research, since they are
similar to humans in several anatomic and physiological charac-
teristics [17,18]. Analogous of different human diseases can also be
found in dogs [18,19]. Use of canine model contributes to eluci-
dating the developmental aspects of stem cell biology and is rele-
vant to the growing market of stem cell therapies that are used for
pets and in preclinical studies for humans [17,20].
Previouslyweandother authors showed that invitro isolated fetal
stem cells distinct properties depends on multiple factors, such as
specie used for cells isolation andgestational age of fetus and speciﬁc
anatomical site (tissue), aswell asmethodof isolationandcell culture
conditions [21]. In this study, we aimed at isolation of canine cells
fromALFandAMFusing fetuses at different gestational ages. In order
to elaborate protocol of efﬁcient ALF and AMF isolation different
methodsandculture conditionswere tested. Immunophenotypingof
ALF and AMF cells have been also performed using several stem cell
markers. Plasticityof these cellswas studied through the inductionof
differentiation toward mesoderm e ectoderm lineages.
2. Materials and methods
2.1. Animals
This study was approved by the Ethical Committee of the School of Veterinary
Medicine and Animal Science of São Paulo University. AMF and ALF were obtained
from 10 mongrel dogs from the Center of Animal Population Control, Sao Paulo,
Brazil. The pregnant uteruses were used after ovarian hysterectomy under general
anesthesia. Sedatives were intravenously administered. The dogs were sedated with
0.1 mg/kg of acepromazine (Acepran, Univet, Sao Paulo, Brazil), 0.5 mg/kg of
xylazine (Anasedan, Vetbrands, Jacareí, Brazil) and 20 mg/kg of ketamine
(Dopolen, Vetbrands, Jacareí, Brazil). Thereafter, the animals were maintained
under inhalation anesthesia (halothane; Cristália, Itapira, Brazil).
2.2. Cell isolation and culture
Samples of AMF and ALF were obtained from fetuses at 50 days of gestation. The
middle gestational age of the fetus was determined in accordance with Evans andTable 1
Culture media used to isolated AMF and ALF cells. Material and Methods.
Number Culture medium composition
1 DMEM-HG supplemented with 10% FBS (cat n12657-029)
and 1% antibiotic solution (Penicillin G 10.00U ¼ mL, 25 mg ¼ mL,
Streptomycin 10.000 mg ¼ mL. All from Invitrogen, Carlsbad,
Calif., USA.
2 DMEM-LG supplemented with 20% certiﬁed FBS (cat n12657-029)
and 1% anibiotic solution (Penicillin G 10.00U ¼ mL, 25 mg ¼ mL,
Streptomycin 10.000 mg ¼ mL), 1% L-glutamine 200 Mm,
and 1% non-essential amino acids. All from Invitrogen, Carlsbad,
Calif., USA.
3 DMEM-LG supplemented with 15% deﬁned FBS (HyClone, Logan,
Utah, USA cat n SH30070-03), 1% antibiotic solution (Penicillin
G 10.00U ¼ mL, 25 mg ¼ mL, Streptomycin 10.000 mg ¼ mL),
1% L-glutamine 200 mM, and 1% non-essential amino acids.
All from reagents from Invitrogen, Carlsbad,Calif., USA.
4 DMEM-HG supplemented with 20% certiﬁed FBS (cat n12657-029)
and 1% anibiotic solution (Penicillin G 10.00U ¼ mL, 25 mg ¼ mL,
Streptomycin 10.000 mg ¼ mL), 1% L-glutamine 200 Mm, and 1%
non-essential amino acids. All from Invitrogen, Carlsbad, Calif., USA.
5 a-MEM supplemented 15% deﬁned FBS (HyClone, Logan, Utah,
USA cat n SH30070-03), 1% antibiotic solution
(Penicillin G 10.00U ¼ mL, 25 mg ¼ mL, Streptomycin 10.000
mg ¼ mL), 1% L-glutamine 200 mM, and 1%no–essential
amino acids. All from reagents from Invitrogen, Carlsbad, Calif., USA.Sack [22]. A total of 5 mL of AMF and ALF samples were collected using a syringe and
a 22 gauge needle (Descarpack, Santa Catarina Brazil). After collection, both ﬂuids
were subjected to two protocols. In the ﬁrst protocol, the ﬂuids were centrifuged at
1000 rpm for 5 min. Supernatants were discarded, and the cell pellets were resus-
pended and plated in culture ﬂasks in basal culture medium. In the second protocol,
the ﬂuids were supplemented with basal culture medium (2 mL of ﬂuid to 3 mL of
medium), plated in 25 cm2 culture ﬂasks (Corning, N.Y., USA) and incubated at 37 C
in a humidiﬁed atmosphere with 5% CO2. The cells were cultured for seven days, the
non-adherent cells were removed, and the medium was replaced. When the cells
reached 70% conﬂuence, they were harvested using a 0.25% trypsin solution (Invi-
trogen, Carlsbad, Calif., USA) and re-plated into 25 cm2 and 75 cm2 ﬂasks. Several
different types of culture media were tested for use in AMF and ALF cell isolation
(Table 1).
2.3. Immunophenotyping
Cells fromAMFand ALFwere grown on coverslips in basal culturemedium. After
48 h, the cells were washed twice in Tris-buffered saline (20 mM TriseHCl pH 7.4 in
0.15 M NaCl) with 0.05% Tween-20 (TBS) and ﬁxed for 24 h in 4% paraformaldehyde
(Gardem Química, Garulhos, Brasil) following permeabilization with 0.1% Triton X-
100 (both from Sigma, St. Louis, Mo.USA). After blocking with 5% bovine serum
albumin, the cells were incubated for 1 h at room temperature with primary anti-
bodies diluted in BSA (Sigma, St. Louis, Mo., USA). The primary antibodies used for
the immunophenotypic proﬁle were as follows: anti-mouse vimentin, anti-mouse
Oct-3/4, (Santa Cruz Biotechnology, California, USA), CK18, (Sigma, St. Louis, Mo.,
USA), anti-human nestin and anti-beta-tubulin III (Chemicon Temecula, Calif., USA).
After washing the cells three times in TBS, ﬂuorescein isothiocyanate (FITC)-
conjugated antibodies were added, and the cells were incubated for 40 min at room
temperature. The following secondary antibodies were used: anti-goat IgG, anti-rat
IgG (Santa Cruz Biotechnology, California, USA), anti-mouse IgG and anti-rabbit IgG
(Amersham Biosciences). Microscope slides were mounted in Vectashield mounting
mediumwith or without 40 ,6-diamidino-2-phenylindol (DAPI) (Vector Laboratories,
Burlingame, CA, USA).
2.4. Confocal microscopy
Images were collected using an LSM 510 (Zeiss) laser scanning confocal micro-
scope. FITC was excited by argon-ion laser set at 488 nm, and the emitted light
ﬁltered using a 505-nm (FITC) long pass ﬁlter. Sections were taken at approximately
the mid-height level of the cells.
2.5. Osteogenic, adipogenic and chondrogenic differentiation assays
All differentiation assays were performed in triplicate. To promote osteo-
genic differentiation, 1  104 cells were plated in six-well plates in basal culture
medium. After 24 h, the medium was changed, and osteogenic medium
composed of DMEM-LG (Invitrogen, Carlsbad, Calif., USA), 2% fetal bovine serum
(FBS) (Invitrogen, Carlsbad, Calif., USA), 50 mM ascorbate-2-phosphate (Invi-
trogen, Carlsbad, Calif., USA) and 0.1 mM dexamethasone (Sigma, St. Louis, Mo.,
USA) was added and changed every 3 days. After 10 days, the osteogenic
medium was supplemented with 10 mM b-glycerol phosphate (Sigma, St. Louis,
Mo., USA). At day 21, the cells were washed twice in PBS, ﬁxed for 24 h in 4%
paraformaldehyde and stained with the von Kossa reagent (Invitrogen, Carlsbad,
Calif., USA).
Adipogenic differentiation was performed according to the protocol for horse
MSCs [23]. Cells were plated on six-well plates (1x104 cells/well). After 24 h,
adipogenic differentiation was induced by the addition of DMEM-HG (Invitrogen,
Carlsbad, Calif., USA) supplemented with 2% FBS (Invitrogen, Carlsbad, Calif.,
USA), 1 mM dexamethasone (Sigma, St. Louis, Mo., USA), 100 mM indomethacin
(Sigma, St. Louis, Mo., USA), 0.5 mM 1-methyl-3-isobutyxanthine (Sigma, St.
Louis, Mo., USA), 10 mg/mL insulin, and 10.000 ug/mL antibiotics (Sigma, St.
Louis, Mo., USA). The medium was changed every 3 days. At day 10, differenti-
ated cells were washed twice in PBS and ﬁxed as described above. Oil Red O
(Sigma, St. Louis, Mo., USA) staining was used to detect intracellular lipid accu-
mulation. St. Louis, Mo., USA).
Chondrogenic differentiation was carried out using a pellet culture technique
[23]. For the preparation of each pellet, the cells were trypsinized and counted, and
2  106 cells were resuspended in culture medium containing DMEM-HG (Invi-
trogen, Carlsbad, Calif., USA) supplemented with 6.25 mg/mL insulin, 6.2 mg/mL
transferrin, 6.25 mg/mL selenous acid, 5.33 mg/mL linoleic acid (ITS; Premix, BD
Biosciences, San Jose, CA), 0.1 mM dexamethasone, 1 mM sodium pyruvate, and
50 mg/mL ascorbate-2-phosphate without transforming growth factor-b1 (TGFb1)
(R&D System, LGC Biotechnology, SP, Brazil). The cells were maintained at 37 C in
a humidiﬁed atmosphere with 5% CO2 for 21 days, and the chondrogenic culture
medium was changed every day. After 21 days, cell aggregates were embedded in
parafﬁn (Media-Paraplast Plus, Oxford Lab., USA). Sections (4e5 mm) were cut
using a Leica microtome and were stained with Masson Trichrome following routine
protocols (Sigma, St. Louis, Mo., USA).
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3.1. Isolation of cells from AMF and ALF
After isolation of the cells from AMF and ALF at earlier canine
gestation stages (at days 25e40), cell adhesion was observed, but
these cells failed to proliferate (Fig. 1A,B). Successful cell isolation
from both AMF and ALF was achieved from pregnant females at 50
days of gestation (Figs. 2A and 3A). Six different types of culture
media were tested (Table 1), and alpha-MEM was chosen due to
good cell yield and active proliferation. Furthermore, cell cultures
from both AMF and ALF were successfully obtained when basal
culture medium (3 mL) was supplemented with aliquots of each
ﬂuid (2 mL). The formation of ﬁbroblast-like cells was observed
around day seven, and the cells from AMF formed more robust cell
culture (Figs. 2A and 3A). Multicellular populations of AMF and ALF
were obtained following in vitro cell expansion and characterized.
3.2. Immunophenotyping of cells from AMF and ALF
The phenotype of cells from both sources was characterized
using immunoﬂuorescence assays (Fig. 2BeD and 3B-D). Cells from
AMF and ALF were stained positively for nestin (Figs. 2B and 3B),
CK18 (Figs. 2C and 3C), and vimentin (Figs. 2D and 3D). The cells
from AMF showed almost uniform immunostaining with nestin
and vimentin, and approximately one third of the cells were
negative for CK18 (Fig. 2C). The majority of the cells from ALF
expressed all three of the markers (Fig. 3BeD).
3.3. Differentiation capacity of cells from AMF and ALF
Osteogenic differentiation of the cells fromAMF occurredwithin
21 days. Formation of a robust extracellular matrix and minerali-
zation was revealed by Von-Kossa staining in the cells from AMF
maintained in culture medium, which induces osteogenic differ-
entiation (Fig. 2E). Control AMF cell culture maintained in basal
culture medium did not show mineralization of extracellular
matrix (data not shown). Use of the same protocol failed to induce
osteogenic differentiation in the cells from ALF (data not shown).
The chondrogenic differentiation capability of cells from both
AMF and ALF was tested with a cell pellet formation protocol. Both
cell types were able to undergo chondrogenic differentiation.
Toluidine blue staining revealed the production of proteoglycans in
the extracellular matrix (data not shown), and Masson Trichrome
staining demonstrated the presence of large collagen areas, which
were more robust in the cell pellet culture from ALF (Figs. 2FeI and
3EeG). Use of a highermagniﬁcation clearly demonstrated collagen
ﬁber formation (Fig. 2GeH and 3F). AMF and ALF maintained in
basal culture medium were not able to form pellets (data not
shown).Fig. 1. Morphology of cell culture derived from canine AMF (A) and ALF (B) atAdipogenic differentiation was induced under conditions that
are routinely used for MSCs, and adipose cell formation was
observed. However, only a limited number of cells from either AMF
or ALF were able to undergo this type of differentiation (Figs. 2J,K
and 3H). Interestingly, under adipogenic differentiation conditions,
the majority of the cells from AMF produced neuron-like cells with
characteristic axon outgrowths (Fig. 2L). Neuronal differentiation is
further supported by staining for beta-tubulin III (Fig. 2MeO).
4. Discussion
We tested two different methods and used several types of
culture media for AMF PS and ALF PS isolation. Dog ﬂuids were
collected and processed following themethods described for human
AMFMSC isolation [9e13]. However, in canines ﬂuids provide a very
small amount of cells, which makes further cell expansion difﬁcult.
The use of the total recoverable volume of the AMF and ALF
improves the process of AMF PS and ALF PS cells isolation. Among
the ﬁve types of culture media used for cell isolation, the alpha-
MEM was shown to be the most adequate for supporting AMF PS
and ALF PS cells growth, proliferation and expansion. In contrast to
a previous study [15], we did not maintain the cells in the presence
of epidermal growth factor (EGF) or any other growth factor. In both
a study by Filioli Urano et al., [2011] and the present work, multi-
cellular population of PS cells were isolated and exhibited similar
cell proliferation rates and viabilities before passage six, and a slow
decline was observed with further passages (data not shown).
Vimentin and nestin are cytoskeletal intermediate ﬁlaments and
are commonly used to deﬁne stem cells. Vimentin is expressed in
various non-epithelial cells, especially in MSCs of fetal and adult
origin (e.g., human termplacenta and amnioticﬂuid) [7,24]. Nestin is
expressed in neural progenitor stem cells and pluripotent stem cells,
whichundergoneuronaldifferentiation, aswell as in immatureMSCs
[25,26]. Recent publications have demonstrated that human AMF
cells express marker of neuronal precursors in particular nestin [27].
Accordingly, expression of both vimentin and nestin were observed
in canine multi-colony-derived AMF PS cells and ALF PS cells in the
present study and inpreviousworks inwhich progenitor/MSCswere
isolated from canine yolk sac, liver and bonemarrow [21]. CK18 is an
intermediate ﬁlament that is associated with epithelial-
mesenchymal cell transition. The expression of CK18 was reported
in fetal liver PCs in mice and in bone-committed progenitors from
umbilical cord [28] aswell as in humanAMFMSCs [29].We observed
expression of CK18 in both AMF PS and ALF PS cells.
Canine AMF MSCs have been shown to express Oct-4 at the 1st
passage [15]. In our study, its expression has not been detected in
canine AMF and or ALF PS cells at the 4and or 5passages (data not
shown). Previously, we detected expression of Oct-4 only in a small
fraction of the canine fetal mesenchymal/progenitor cells isolated
from the yolk sac and liver [21]. Although some human MSCs fromday 25 of dog gestation. Light microscopy (LM). Scale bars: A, B ¼ 5 mm.
Fig. 3. ALF PS cells. A) Cell morphology. B-D) Expression of epithelial-mesodermal markers in ALF PS cells: B) Nestin-positive cells; white arrows show nestin-negative cells; C)
Cytokeratin 18, D) Vimentin. Inset shows the negative control for B,C also (white arrow) in which the primary antibody was omitted. Nuclei stained with DAPI (blue). E-G)
Chondrogenic differentiation: E,F) Black arrows indicate collagen ﬁbers,Masson Trichrome staining (HM); G) Toluidine blue staining reveals production of proteoglycans. H) Adi-
pogenic differentiation; Oil red O staining reveals lipid drops (white arrows) in the cytoplasm of adipose cells. A ¼ PC; B-D ¼ FM, E-G ¼ LM. Scale bars: A,C,D ¼ 10 mm, B,H ¼ 5 mm;
E ¼ 500 mm; F,G ¼ 50 mm.
Fig. 2. AMF PS cells. A) Cell morphology. B-D) expression of epithelial-mesodermal markers in AMF PS cells: B) Nestin; C) Cytokeratin 18; Inset shows the negative control for B,D
also (white arrow) in which the primary antibody was omitted; D) Vimentin; inset shows the localization of vimentin (white arrow) on cytoskeleton ﬁlaments. Nuclei stained with
DAPI (blue). E-M) Differentiation potential of AMF PS cells: E) Osteogenic differentiation, (white arrow) Von-Kossa staining. F-I) Chondrogenic differentiation. F-H) Collagen ﬁbers
formation as assayed by Masson Trichrome staining. I) Toluidine blue staining reveals production of proteoglycans. J,K) Adipogenic differentiation; Oil red O staining reveals lipid
droplets (black arrows) in the cytoplasm of adipose cells. L) Neuron-like cells (black arrowhead) with axon outgrowth; black arrows indicate adipose cells. MeO) Expression of beta-
tubulin III (green). White arrowheads indicate neuron body, while arrows show axons formation. A ¼ phase contrast (PC); B-D ¼ ﬂuorescent microscopy (FM), I-L ¼ LM,
M ¼ FM þ digital interference contrast (DIC). Scale bars: A,K,M,N, O ¼ 20 mm, B,D, J,L ¼ 5 mm, C,E ¼ 10 mm, F,I-H ¼ 100 mm.
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undergo adipogenic and osteogenic differentiation [4,10].
ALF PS cells showed differentiation toward chondrogenic and
adipogenic lineages, but they were unable to differentiate into the
osteogenic lineage. It is commonly accepted that vertebrate skel-
etogenesis requires a well-coordinated transition from chondro-
genesis to osteogenesis. During this process, the replacement of
cartilagewith bone occurs, and this process is tightly coordinated in
time and space by molecular mechanisms and by an appropriate
cellular environment [30]. It is possible that the inability of ALF PS
cells to differentiate into osteogenic lineages in vitro is due to the
strong chondrogenic commitment of these cells, which is consis-
tent with the role of the allantois in development. Thus, although
ALF cells lack MSC properties, they may potentially represent
a valuable source for cartilage tissue engineering and related stem
cell therapies. Similar reported previously, we demonstrated that
canine AMF PS cells showed mesodermal and ectodermal differ-
entiation potential [15].5. Conclusions
According to the present deﬁnition set by the Mesenchymal and
Tissue Stem Cell Committee of the International Society for Cellular
Therapy [31], the cells from AMF obtained in the present work can
be classiﬁed as multipotent PS cells, whereas the cells from ALF can
be classiﬁed as bi-potential PCs. We demonstrated that the isola-
tion and expansion of PS cells occurred when the AMF and ALF
were collected at the third gestational trimester. Although at earlier
gestational stages, cell adhesion was observed, these cells cultured
under the same conditions failed to proliferate (Fig. 1). Indeed,
canine AMF MSCs were already obtained by another group;
however the canine fetal age was not reported [15]. The discrep-
ancies in fetal stem cells characteristics between different studies
warrant further investigation of extra-embryonic tissues as
a source of MSCs and PS cells. Comparative studies between
embryonic, fetal and adult stem cells in different mammalian
species can contribute signiﬁcantly to our knowledge of stem cell
biology and the functional versatility of stem cells [32]. Neverthe-
less, fetal ﬂuids are an accessible source of MSCs and progenitor/
stem cells that exhibit low immunogenicity [6].
References
[1] De Sacco S, Sedrakyan S, Boldrin F, Giuliani S, Parnigotto P, Habibian R, et al.
Human amniotic ﬂuid as a potential new source of organ speciﬁc precursor
cells for future regenerative medicine applications. J Urol 2010;183(3):
1193e2000.
[2] Klemmt PA, Vafaizadeh V, Groner B. Murine amniotic ﬂuid stem cells
contribute mesenchymal but not epithelial components to reconstituted
mammary ducts. Stem Cell Res Ther 2010;1(3):20.
[3] Cananzi M, Atala A, De Coppi P. Stem cells derived from amniotic ﬂuid: new
potentials in regenerative medicine. Reprod Biomed 2009;18(Suppl. 1):
17e27. Online.
[4] In ’t Anker PS, Scherjon SA, Kleijburg-van der Keur C, Noort WA, Claas FH,
Willemze R, et al. Amniotic ﬂuid as a novel source of mesenchymal stem cells
for therapeutic transplantation. Blood 2003;102(4):1548e9.
[5] De Coppi P, Bartsch G, Siddiqui MM, Xu T, Santos CC, Perin L, et al. Isolation of
amniotic stem cell lines with potential for therapy. Nat Biotechnol 2007;25(1):
100e6.
[6] Parolini O, Alviano F, Bergwerf I, Boraschi D, De Bari C, DeWaele P. Toward cell
therapy using placenta-derived cells: disease mechanisms, cell biology,
preclinical studies, and regulatory aspects at the round table. Stem Cells Dev
2010;19:143e54.[7] Prusa AR, Marton E, Rosner M, Bernaschek G, Hengtshlager M. Oct-4
expressing cells in human amniotic ﬂuid: a new source for stem cell research?
Hum Reprod 2003;18(7):1489e93.
[8] Antonucci I, Stuppia l, Kaneko Y, Yu S, Tajiri I, Bae EC, et al. Amniotic ﬂuid as
Rich source of mesenchymal stromal cells for transplantation therapy. Cell
Transplantation. 2011;20(6):789e95.
[9] Tsai MS, Lee JL, Chang YJ. Isolation of human multipotent mesenchymal stem
cells from second trimester amniotic ﬂuid using a novel two-stage culture
protocol. Hum Reprod 2004;19(6):1450e7.
[10] Bossolasco P, Tiziana Montemurro T, Cova L. Molecular and phenotypic
characterization of human amniotic ﬂuid cells and their differentiation
potential. Cell Res 2006;16(4):329e36.
[11] De Coppi P, Bartsch Jr G, Siddiqui M, Xu T, Santos CC, Perin L, et al. Isolation of
amniotic stem cell lines with potential for therapy. Nat Biotechnol 2007;
25(1):100e6.
[12] Tsai MS, Hwang SM, Tsai YL, Chang FC, Lee J, Changy J. Clonal amniotic ﬂuid-
derived stem cells express characteristics of both mesenchymal and neural
stem cells. Biol Reprod 2006;74(3):545e51.
[13] Siegel N, Rosner M, Hanneder M, Valli A, Hengstschlager M. Stem cells in
amniotic ﬂuid as new tools to study human genetic diseases. Stem Cell Rev
2007;3(4):256e64.
[14] Kaviani A, Perry TE, Dzakovic A, Jennings RW, Ziegler MM, Fauza DO. The
amniotic ﬂuid as a source of cells for fetal tissue engineering. J Pediatr Surg
2001;36:1662e5.
[15] Filioli Urano M, Valentini L, Lange-Consiglio A, Caira M, Guaricci C, Labbate A,
et al. Isolation, proliferation, Cytogenetic, and molecular characterization and
in vitro differentiation Potency of canine stem cells from Foetal Adnexa:
a comparative study of amniotic ﬂuid, Amnion, and umbilical cord matrix. Mol
Reprod Dev 2011;78(5):361e73.
[16] Dieterlen-Lièvre F, Corbel C, Salaün J. Allantois and placenta as developmental
sources of hematopoietic stem cells. Int J Dev Biol 2010;54(6e7):1079e87.
[17] Hoorn PA, Morris JC, Neff T, Kiem HP. Stem cell gene transfereefﬁcacy and
safety in large animal studies. Mol Ther 2004;40(3):417e31.
[18] Parker HG, Ostrander EA. Canine genomics and genetics: running with the
pack. PLoS Genet 2005;1(5):507e12.
[19] Kirkness E, Bafna V, Halpern AL, Levy S, Remington K, Rusch DB, et al. The dog
genome: survey sequencing and comparative analysis. Science 2003;301:
1898e903.
[20] Wagner JL, Storb R. Preclinical large animal models for hematopoietic stem
cell transplantation. Curr Opin Hematol 1996;3:410.
[21] Wenceslau CV, Miglino MA, Martins DS, Ambrósio CE, Lizier NF, Pignatari GC,
et al. Mesenchymal progenitor cells from canine fetal tissues: yolk sac, liver
and bone marrow. Tissue Eng Part A 2011;17-18:2165e76.
[22] Evans HE, Sack WO. Prenatal development of domestic e laboratory
mammals: growth curves, external features e selected references. Anat Histol
Embryol 1973;2:11e45.
[23] Mambelli LI, Santos EJC, Frazaão PR, Chaparro MB, Kerkis A, Zoppa AL, et al.
Characterization of Equine adipose TissueeDerived progenitor cells before
and after Cryopreservation. Tissue Eng Part C 2009;15:87e94.
[24] Kanematsu D, Shofuda T, Yamamoto A, Ban C, Ueda T, Yamasaki M, et al.
Isolation and cellular properties of mesenchymal cells derived from the
decidua of human term placenta. Differentiation 2007;82:77e88.
[25] Nagai A, Kim WK, Lee HJ, Jeong HS, Kim KS, Hong SH, et al. Multilineage
potential of stable human mesenchymal stem cell line derived from fetal
marrow. PLoS One 2007;2:127e30.
[26] Vogel W, Grunebach F, Messam CA, Kanz LW, Brugger W, Buhring HJ.
Heterogeneity among human bone marrow-derived mesenchymal stem cells
and neural progenitor cells. Haematologógica 2003;88(2):126e33.
[27] Prusa AR, Erika Marton E, Rosner M, Bettelheim D, Lubec G, Arnold Pollack A,
et al. Neurogenic cells in human amniotic ﬂuid. Am J Obstetrics Gynecol 2004;
191(1):309e14.
[28] Rosada C, Justesen J, Melsvik D, Ebbesen P, Kassem M. The human umbilical
cord blood: a potential source for osteoblast progenitor cells. Calcif Tissue Int
2003;72(2):135e42.
[29] Kim J, Lee Y, Kim H, Hwang KJ, Kwon H, Kim SK, et al. Human amniotic ﬂuid-
derived stem cells have characteristics of multipotent stem cells. Cell Prolif
2007;40(1):75e90.
[30] Chung U, Schipani E, McMahon AP, Kronenberg HM. Indian hedgehog couples
chondrogenesis to osteogenesis in endochondral bone development. J Clin
Invest 2001;107(2):295e304.
[31] Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS,
et al. Minimal criteria for deﬁning multipotent mesenchymal stromal cells.
The International Society for Cellular Therapy position statement. Cytotherapy
2006;8(4):315e7.
[32] Manuelpillai U, Moodley Y, Borlongan CV, Parolini O. Amniotic membrane and
amniotic cells: potential therapeutic tools to combat tissue inﬂammation and
ﬁbrosis? Placenta 2011;32:S320e5.
